Common Side Effects of Tremfya
Tremfya (guselkumab), an IL-23 inhibitor for psoriatic arthritis, commonly causes upper respiratory infections (like colds), headache, fatigue, diarrhea, and injection-site reactions such as redness or pain.[1][2] These affect 5-10% of patients in clinical trials and are usually mild.
Serious Side Effects and Risks
Serious risks include infections (e.g., tuberculosis reactivation), hypersensitivity reactions (rash, swelling, breathing issues), and increased malignancy risk. It carries a boxed warning for serious infections due to immunosuppression. Liver enzyme elevations occur in some cases, and avoid live vaccines during treatment.[1][2][3]
Side Effects Specific to Psoriatic Arthritis Use
In psoriatic arthritis trials (like DISCOVER-1 and -2), infections topped the list at 22-27% vs. 20% placebo, with herpes infections and fungal issues more frequent. Arthralgia and back pain were noted but often tied to the condition itself.[2][3]
How Long Do Side Effects Last?
Most resolve within days to weeks; injection reactions fade in 1-3 days. Persistent infections or hypersensitivity may require stopping treatment.[1]
Who Gets Side Effects Most?
Higher rates in patients with infection history, diabetes, or immunosuppression. Monitor elderly patients closely for infections.[1][2]
Managing Side Effects
Screen for TB and hepatitis before starting. Report fever, cough, or unusual fatigue promptly. Use pre-filled syringes or autoinjectors to minimize injection issues.[1][3]
[1] Tremfya Prescribing Information, Janssen Pharmaceuticals, https://www.tremfya.com/psoriatic-arthritis/pi
[2] FDA Label for Guselkumab, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761029s029lbl.pdf
[3] DISCOVER Trial Data, New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa2002512